Loading...

DBVT DBV TECHNOLOGIES SA Management Changes 8-K Filing

DBV

DBVT

DBV TECHNOLOGIES SA

(DBVT)

2025 8-K

Show Summary

Summary

New Product Launches

Compensatory Arrangements o...

Financial Statements

Private Placement

Financial Results

Positive Study Results

Management Changes

Nasdaq Compliance

FDA Approval Pathway

ADS Ratio Change

Financial Results

Financial Update

Clinical Trial Update

Earnings Report

Ratio Change Announcement

Ratio Change of ADSs

Amendments to Bylaws and Sh...

Earnings Report

Financial Results and Busin...

Appointment of CFO

Amendment to Form 8-K/A

Termination of Agreement

Appointment of CFO and Depa...

Earnings Report

Publication of Phase 3 EPIT...

Earnings Report

Financial Condition and Oth...

Annual General Meeting

Regulation FD Disclosure

Clinical Trial Announcement

Financial Results Announcement

External Links:

On June 11, 2025, DBV Technologies S.A.'s shareholders approved the 2024 compensation for its CEO, which includes $348,000 in variable compensation and a $150,000 bonus. They also voted on several resolutions related to bylaw amendments and financial statements for 2024.

AI Assistant

DBV TECHNOLOGIES SA

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.